title: Second study shows that octreotide may prevent early rebleeding in cirrhosis.
authors.forename: G
authors.initials: G
authors.lastname: D'Amico
authors.forename: F
authors.initials: F
authors.lastname: Politi
authors.forename: A
authors.initials: A
authors.lastname: D'Antoni
authors.forename: G
authors.initials: G
authors.lastname: Giannuoli
authors.forename: L
authors.initials: L
authors.lastname: Pasta
authors.forename: G
authors.initials: G
authors.lastname: Vizziani
authors.forename: M
authors.initials: M
authors.lastname: Traina
authors.forename: A
authors.initials: A
authors.lastname: Morabito
authors.forename: L
authors.initials: L
authors.lastname: Pagliaro
mesh_terms: D000319:Adrenergic beta-Antagonists / Q000627:therapeutic use*; D004311:Double-Blind Method; D004932:Esophageal and Gastric Varices / Q000188:drug therapy*; D005765:Gastrointestinal Agents / Q000627:therapeutic use*; D006471:Gastrointestinal Hemorrhage / Q000517:prevention & control*; D006801:Humans; D008103:Liver Cirrhosis / Q000150:complications; D015282:Octreotide / Q000627:therapeutic use*; D012008:Recurrence; D015911:Sclerotherapy / Q000379:methods
chemical_list: D000319:Adrenergic beta-Antagonists; D005765:Gastrointestinal Agents; D015282:Octreotide